A Phase 4 interventional study of Ranolazine and Placebo in Coronary Artery Disease, Pain and Peripheral Nervous System Diseases, sponsored by Gilead Sciences. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-30.
Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing ranolazine in Coronary Artery Disease — none open to participants now, none under way, none of them phase 3. Ranolazine · Coronary Artery Disease.
Among the 15 studies testing ranolazine in Coronary Artery Disease, this one is the 13th largest by enrollment, is the only one that started in 2009, is one of 8 in phase 4, and was the 2nd registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →None of the 15 studies testing ranolazine in Coronary Artery Disease is open now. The open studies under Coronary Artery Disease, anywhere →
Ranolazine: first FDA approval 2006 (RANEXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 5 · Phase 4 8
First in 2004; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 124 across 3,010 interventional studies indexed under Coronary Artery Disease.
Median enrollment 50 across the 15 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 15 have an industry lead sponsor. The 9 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
10 studies in Coronary Artery Disease by Gilead Sciences: none open now, none under way, none of them phase 3. Of 8 finished, 3 (38%) have results posted.
Among the 10 studies in Coronary Artery Disease by Gilead Sciences, this one is the 8th largest by enrollment, is one of 2 that started in 2009, is one of 3 in phase 4, and was the 4th registered.
Gilead Sciences’s Coronary Artery Disease studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing ranolazine in Coronary Artery Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 10 in Coronary Artery Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease.
Eligibility required neurological examination by the study doctor and assessment of the patient's pain. Eligible participants were randomized to receive blinded study medication for a total of 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were randomized to receive placebo to match ranolazine during Weeks 1 to 6, then ranolazine during Weeks 7 to 12.
Drug: Ranolazine · Drug: Placebo
Participants were randomized to receive ranolazine during Weeks 1 to 6, then placebo to match ranolazine during Weeks 7 to 12.
Drug: Ranolazine · Drug: Placebo
Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).
Also known as: Ranexa
Placebo to match ranolazine administered twice a day for 6 weeks
Reduction in Neuropathic Pain
Reduction in patient-reported neuropathic pain (by 2 numeric levels as measured by the Numeric Pain Scale)
Time frame: Baseline to Week 6
Assess Participant Quality of Life Utilizing the Short Form 36 Health Survey (SF-36v2) Questionnaire
The participant quality of life assessed utilizing the SF-36v2 questionnaire
Time frame: Baseline to Week 6
Response to Thermal and Mechanical Stimuli
The participant response to thermal and mechanical stimuli as measured by the Hargreaves and Von Frey tests
Time frame: Baseline to Week 6
Five participants were enrolled and treated.
| Milestone | Placebo/Ranolazine | Ranolazine/Placebo |
|---|---|---|
| Started | 3 | 2 |
| Completed | 3 | 2 |
| Not completed | 0 | 0 |
| Milestone | Placebo/Ranolazine | Ranolazine/Placebo |
|---|---|---|
| Started | 3 | 2 |
| Completed | 3 | 2 |
| Not completed | 0 | 0 |
Reduction in patient-reported neuropathic pain (by 2 numeric levels as measured by the Numeric Pain Scale)
No measurements were reported for this outcome.
The participant quality of life assessed utilizing the SF-36v2 questionnaire
No measurements were reported for this outcome.
The participant response to thermal and mechanical stimuli as measured by the Hargreaves and Von Frey tests
No measurements were reported for this outcome.
Collected over Up to 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/Ranolazine, Period 1 | — | 0/3 (0%) | 1/3 (33.3%) |
| Placebo/Ranolazine, Period 2 | — | 0/3 (0%) | 0/3 (0%) |
| Ranolazine/Placebo, Period 1 | — | 0/2 (0%) | 0/2 (0%) |
| Ranolazine/Placebo, Period 2 | — | 0/2 (0%) | 1/2 (50%) |
| Event | Placebo/Ranolazine, Period 1 | Placebo/Ranolazine, Period 2 | Ranolazine/Placebo, Period 1 | Ranolazine/Placebo, Period 2 |
|---|---|---|---|---|
| FeverGeneral disorders | 0/3 | 0/3 | 0/2 | 1/2 |
| ChillsGeneral disorders | 0/3 | 0/3 | 0/2 | 1/2 |
| HeadacheNervous system disorders | 0/3 | 0/3 | 0/2 | 1/2 |
| Sensitivity to light (eyes)Nervous system disorders | 0/3 | 0/3 | 0/2 | 1/2 |
| Right leg muscle tendon pulledMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/2 | 1/2 |
| Stabbing pain to right leg calfMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/2 | 1/2 |
| Aching pain to right calfMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/2 | 1/2 |
| Expiratory wheezingMusculoskeletal and connective tissue disorders | 1/3 | 0/3 | 0/2 | 0/2 |
All enrolled and treated participants
| Age, Categorical(Participants) | Placebo/Ranolazine | Ranolazine/Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 2 | 2 |
| >=65 years | 3 | 0 | 3 |
| Sex: Female, Male(Participants) | Placebo/Ranolazine | Ranolazine/Placebo | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 2 | 1 | 3 |
The record gives a start of Jan 2009, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 5 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranolazine